Early Clinical Experience with the On-X Valve...
Early Clinical Experience with the On-X Valve...
I found this paper, Westie...
http://icvts.ctsnetjournals.org/cgi/content/full/4/6/588
And, "after almost one decade of clinical experience in a single center," this information:
http://www.icr-heart.com/journal/content/2007/sept/abstracts/article.php?id=14
"Single-Center Experience with the On-X Prosthetic Heart Valve between 1996 and 2005
Paschalis Tossios MD, Delawer Reber MD, Maria Oustria, Tim Holland-Letz PhD, Alfried Germing MD, Dirk Buchwald, Axel Laczkovics MD
Departments of Cardiothoracic Surgery, Medical Informatics, Biometry and Epidemiology and Cardiology, BG Universitätsklinikum Bergmannsheil, University of Bochum, Bochum, Germany
Background and aim of the study: Herein are presented long-term results for the On-X mechanical heart valve. All On-X heart valve recipients since the first implantation worldwide at the University of Bochum in September 1996 were followed retrospectively; the present authors’ single-center experience over a period of almost 10 years is reported.
Methods: A total of 428 patients (255 males, 173 females; mean age 62.7 years) underwent either aortic valve replacement (AVR; n = 264) or mitral valve replacement (MVR; n = 164) using the On-X prosthesis. Preoperatively, 329 patients (76.8%) were in NYHA class III or IV. Approximately 5% of AVR and 23% of MVR patients had undergone previous cardiac surgery. Concomitant surgery was performed in 189 patients (44.2%). The mean follow up was 3.9 years, and cumulative follow up 1,625 patient-years (pt-yr); the overall follow up rate was 98.7%.
Results: Early mortality (≤30 days) was 3.7% after
AVR and 14.0% after MVR, with valve-related mortality rates of 0.4% and 1.2%, respectively. At autopsy (n = 12) all implants were intact. Freedom from valve-related death at nine years was 85.0 ± 3.9% after AVR and 87.6 ± 3.2% after MVR. The overall survival rate was 67.9 ± 4.3% after AVR and 52.7 ± 8.1% after MVR. The linearized rate of thromboembolism for AVR and MVR was 1.49%/pt-yr and 1.61%/pt-yr; of thrombosis 0%/pt-yr and 0.35%/pt-yr; of hemorrhage 0.93%/pt-yr and 1.43%/pt-yr; of endocarditis 0.37%/pt-yr and 0.17%/pt-yr; of non-structural failure 0.18%/pt-yr and 1.43%/pt-yr; and of reoperation 0.28%/pt-yr and 0.53%/pt-yr. There were no cases of structural valve failure.
Conclusion:
After almost one decade of clinical experience in a single center, the On-X heart valve continues to be reliable and effective.
The Journal of Heart Valve Disease 2007;16:551-557"